SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	May 26, 2021	Dec. 31, 2021	Dec. 31, 2020
Accumulated deficit		$ (94,446,000)	$ (81,253,000)
Allowance for doubtful accounts		80,000.00	40,000.00
Cure Pharmaceutical Revenue		$ 300,000
AgreementTerm		5 years
Payment fordeveloped production line		$ 300,000
Contract liabilities		500,000	1,000,000.0
Advertising costs		2,800,000	1,100,000
Research and development expenses		$ 2,400,000	2,800,000
Valuation allowance percentage		100.00%
Amount in excess of FDIC limit			1,500,000
RequestForConversionDescription		the Company purchased Convertible Loans (“Loans”) from Releaf Europe BV (“Releaf”) in the amount of $0.5 million. Releaf shall accrue interest on the Loans at 6% per annum and shall become due and payable to the Company at the earlier of the conversion date, the date when the Loans are repaid or at the maturity date of October 31, 2021 (“Maturity Date”). In the event of a request for conversion by the Company (“Request for Conversion”) or at the end of the Maturity Date, the outstanding amount of the Loans and any unpaid accrued interest shall be converted into shares of Releaf (“Shares”) based on a price per share on a post money valuation of $10.9 million. In the event Releaf completes a financing round totaling at least $2 million of debt and/or equity (“Qualified Financing”), the outstanding amount of the Loan Agreement and any unpaid accrued interest shall automatically convert at a price per share paid by the investors in connection with the Qualified Financing less a discount of 20% on the subscription price.
Qualified Financing conversion	$ 4,000,000	$ 15,000,000
Valuation Financing conversion		14,500,000
Working capital deficit		22,500,000
FDIC insured amount		250,000
Cash in hand		16,000	$ 1,725,000
Cash [Member]
Cash in hand		$ 20,000.00